Claims for Patent: 10,047,153

Summary for Patent: 10,047,153

Title:	Human antibodies to Fel d1 and methods of use thereof
Abstract:	The present invention provides antibodies that bind to the cat allergen, Fel d1, compositions comprising the antibodies, nucleic acids encoding the antibodies and methods of use of the antibodies. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Fel d1. The antibodies of the invention are useful for binding to the Fel d1 allergen in vivo, thus preventing binding of the Fel d1 allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and/or basophils, thus ameliorating the untoward response to the cat allergen in sensitized individuals. The antibodies of the invention may also be useful for diagnostic purposes to determine if a patient is allergic to the Fel d1 cat allergen.
Inventor(s):	Orengo; Jamie (Cortlandt Manor, NY), Murphy; Andrew J. (Croton-on-Hudson, NY)
Assignee:	REGENERON PHARMACEUTICALS, INC. (Tarrytown, NY)
Application Number:	15/416,176
Patent Claims:	1. An isolated human monoclonal antibody or antigen-binding fragment thereof that binds specifically to Fel d1, wherein the antibody comprises the three heavy chain CDRs (HCDR1, HCDR2 and HCDR3) contained within any one of the heavy chain variable region (HCVR) sequences selected from the group consisting of SEQ ID NOs: 2, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274, 290, 306, 322, 338, 354 and 370; and the three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained within any one of the light chain variable region (LCVR) sequences selected from the group consisting of SEQ ID NOs: 10, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, 314, 330, 346, 362, and 378. 2. The isolated human monoclonal antibody or antigen-binding fragment thereof of claim 1, wherein the human antibody or antigen-binding fragment thereof binds specifically to Fel d1 with a K.sub.D equal to or less than 10.sup.-6 M, as measured by surface plasmon resonance. 3. The isolated human monoclonal antibody or antigen-binding fragment thereof of claim 1, comprising a HCVR having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274, 290, 306, 322, 338, 354, and 370. 4. The isolated human monoclonal antibody or antigen-binding fragment thereof of claim 1, comprising a LCVR having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, 314, 330, 346, 362, and 378. 5. The isolated human monoclonal antibody or antigen-binding fragment thereof of claim 1, comprising: (a) a HCVR having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274, 290, 306, 322, 338, 354 and 370; and (b) a LCVR having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, 314, 330, 346, 362 and 378. 6. The isolated human monoclonal antibody or antigen-binding fragment thereof of claim 1, comprising: (a) a HCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 36, 52, 68, 84, 100, 116, 132, 148, 164, 180, 196, 212, 228, 244, 260, 276, 292, 308, 324, 340, 356 and 372; (b) a HCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 38, 54, 70, 86, 102, 118, 134, 150, 166, 182, 198, 214, 230, 246, 262, 278, 294, 310, 326, 342, 358 and 374; (c) a HCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 40, 56, 72, 88, 104, 120, 136, 152, 168, 184, 200, 216, 232, 248, 264, 280, 296, 312, 328, 344, 360 and 376; (d) a LCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 44, 60, 76, 92, 108, 124, 140, 156, 172, 188, 204, 220, 236, 252, 268, 284, 300, 316, 332, 348, 364 and 380; (e) a LCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 46, 62, 78, 94, 110, 126, 142, 158, 174, 190, 206, 222, 238, 254, 270, 286, 302, 318, 334, 350, 366 and 382; and (f) a LCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 16, 48, 64, 80, 96, 112, 128, 144, 160, 176, 192, 208, 224, 240, 256, 272, 288, 304, 320, 336, 352, 368 and 384. 7. The isolated human monoclonal antibody or antigen-binding fragment of claim 1, comprising a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 226/234, 242/250, 258/266, 274/282, 290/298, 306/314, 322/330, 338/346, 354/362 and 370/378. 8. The isolated human monoclonal antibody or antigen-binding fragment of claim 1, comprising three HCDRs and three LCDRs contained within the HCVR/LCVR amino acid sequence pair of SEQ ID NOs: 306/314. 9. The isolated human monoclonal antibody or antigen-binding fragment of claim 1, wherein the antibody or fragment thereof interacts with at least one amino acid sequence selected from group consisting of amino acid residues ranging from about position 15 to about position 24 of SEQ ID NO: 396; amino acid residues ranging from about position 85 to about position 103 of SEQ ID NO: 396; amino acid residues ranging from about position 85 to about position 104 of SEQ ID NO: 396; and amino acid residues ranging from about position 113 to about position 127 of SEQ ID NO: 396. 10. The isolated human monoclonal antibody or antigen binding fragment thereof of claim 9, wherein the antibody or fragment thereof interacts with amino acid residues ranging from about position 15 to about position 24 of SEQ ID NO: 396. 11. The isolated human monoclonal antibody of claim 9, or an antigen binding fragment thereof, wherein the antibody or fragment thereof interacts with amino acid residues ranging from about position 85 to about position 103 of SEQ ID NO: 396. 12. The isolated human monoclonal antibody of claim 9, or an antigen binding fragment thereof, wherein the antibody or fragment thereof interacts with amino acid residues ranging from about position 85 to about position 104 of SEQ ID NO: 396. 13. The isolated human monoclonal antibody of claim 9, or an antigen binding fragment thereof, wherein the antibody or fragment thereof interacts with amino acid residues ranging from about position 113 to about position 127 of SEQ ID NO: 396. 14. The isolated human monoclonal antibody of claim 1, or an antigen binding fragment thereof, wherein the antibody or fragment thereof interacts with at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 402, 403, 404 and 412. 15. The isolated human monoclonal antibody of claim 14, or an antigen binding fragment thereof, wherein the antibody or fragment thereof interacts with SEQ ID NO: 402. 16. The isolated human monoclonal antibody of claim 14, or an antigen binding fragment thereof, wherein the antibody or fragment thereof interacts with SEQ ID NO: 403. 17. The isolated human monoclonal antibody of claim 14, or an antigen binding fragment thereof, wherein the antibody or fragment thereof interacts with SEQ ID NO: 404. 18. The isolated human monoclonal antibody of claim 14, or an antigen binding fragment thereof, wherein the antibody or fragment thereof interacts with SEQ ID NO: 412. 19. A pharmaceutical composition comprising a therapeutically effective amount of one or more isolated human monoclonal antibodies, or antigen-binding fragments thereof, of claim 1, together with one or more pharmaceutically acceptable excipients. 20. The pharmaceutical composition of claim 19, comprising: a) a first isolated human monoclonal antibody, or antigen-binding fragment thereof, having a HCVR/LCVR amino acid sequence pair of SEQ ID NOs: 306/314; and b) one or more isolated human monoclonal antibodies, or antigen-binding fragments thereof, selected from the group consisting of the HCVR/LCVR amino acid sequence pairs of SEQ ID NOs: 66/74, 130/138, 162/170, 242/250, 322/330, and 370/378. 21. The pharmaceutical composition of claim 19, comprising: a) a first isolated human monoclonal antibody, or antigen-binding fragment thereof, having a HCVR/LCVR amino acid sequence pair of SEQ ID NOs: 306/314; and b) one or more isolated human monoclonal antibodies, or antigen-binding fragments thereof, selected from the group consisting of the HCVR/LCVR amino acid sequence pairs of SEQ ID NOs: 242/250 and 322/330. 22. The pharmaceutical composition of claim 19, comprising: a) a first isolated human monoclonal antibody, or antigen-binding fragment thereof, having a HCVR/LCVR amino acid sequence pair of SEQ ID NOs: 306/314; and b) a second isolated human monoclonal antibody, or antigen-binding fragment thereof, having a HCVR/LCVR amino acid sequence pair of SEQ ID NOs: 130/138. 23. The pharmaceutical composition of claim 19, comprising: a) a first isolated human monoclonal antibody, or antigen-binding fragment thereof, having a HCVR/LCVR amino acid sequence pair of SEQ ID NOs: 306/314; and b) a second isolated human monoclonal antibody, or antigen-binding fragment thereof, having a HCVR/LCVR amino acid sequence pair of SEQ ID NOs: 322/330. 24. The pharmaceutical composition of claim 19, comprising: a) a first isolated human monoclonal antibody, or antigen-binding fragment thereof, having a HCVR/LCVR amino acid sequence pair of SEQ ID NOs: 306/314; and b) a second isolated human monoclonal antibody, or antigen-binding fragment thereof, having a HCVR/LCVR amino acid sequence pair of SEQ ID NOs: 66/74. 25. The pharmaceutical composition of claim 19, comprising: a) a first isolated human monoclonal antibody, or antigen-binding fragment thereof, having a HCVR/LCVR amino acid sequence pair of SEQ ID NOs: 306/314; and b) a second isolated human monoclonal antibody, or antigen-binding fragment thereof, having a HCVR/LCVR amino acid sequence pair of SEQ ID NOs: 370/378. 26. The pharmaceutical composition of claim 19, comprising three isolated human monoclonal antibodies, or antigen-binding fragments thereof, wherein the human antibodies or antigen-binding fragments thereof comprise the HCVR/LCVR amino acid sequence pairs of SEQ ID NOs: 306/314, 242/250 and 322/330. 27. The pharmaceutical composition of claim 19, comprising: a) a isolated first human monoclonal antibody, or antigen-binding fragment thereof, having a HCVR/LCVR amino acid sequence pair of SEQ ID NOs: 306/314; and b) a second isolated human monoclonal antibody, or antigen-binding fragment thereof, having a HCVR/LCVR amino acid sequence pair of SEQ ID NOs: 162/170. 28. The pharmaceutical composition of claim 19, comprising three isolated human monoclonal antibodies, or antigen-binding fragments thereof, wherein the human antibodies or antigen-binding fragments thereof comprise the HCVR/LCVR amino acid sequence pairs of SEQ ID NOs: 306/314, 18/26, and 370/376. 29. A method for treating a patient who demonstrates a sensitivity to, or an allergic reaction against, a cat, cat dander, cat hair or an extract thereof, or to Fel d1 protein, or for treating at least one symptom or complication associated with a sensitivity to, or allergic reaction against a cat, cat dander, cat hair or an extract thereof, or to Fel d1 protein, comprising administering an effective amount of one or more isolated human monoclonal antibodies or antigen-binding fragments thereof that bind specifically to Fel d1, according to claim 1 to a patient in need thereof, wherein the sensitivity to, or an allergic reaction against, a cat, cat dander, cat hair or an extract thereof, or to Fel d1 protein is lessened in severity and/or duration, or at least one symptom or complication associated with the sensitivity to, or allergic reaction against, a cat, cat dander, cat hair or an extract thereof, or to Fel d1 protein is ameliorated, or that the frequency and/or duration of, or the severity of the sensitivity to or allergic reaction against, a cat, cat dander, cat hair or an extract thereof, or to Fel d1 protein is reduced following administration of one or more of the isolated human monoclonal antibodies or fragments thereof that bind specifically to Fel d1. 30. The method of claim 29, further comprising administering an effective amount of a second therapeutic agent useful for diminishing an allergic reaction to a cat, cat dander, cat hair or an extract thereof, or to Fel d1 protein. 31. The method of claim 30, wherein the second therapeutic agent is selected from the group consisting of a corticosteroid, a bronchial dilator, an antihistamine, epinephrine, a decongestant, another different antibody to Fel d1 and a peptide vaccine. 32. The method of claim 29, wherein the treatment results in a reduction in allergic rhinitis, allergic conjunctivitis, allergic asthma, or an anaphylactic response following exposure of the patient to a cat, cat dander, cat hair or an extract thereof, or to Fel d1 protein.

Details for Patent 10,047,153

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Allermed Laboratories, Inc.	N/A	animal allergens, standardized cat hair	Injection	103473	03/12/1974		2032-05-03